Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.35 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2989718 | 0.97 | ALDH1A1 (0.44) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL28293684 | 0.95 | ALDH1A1 (0.42) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL8721639 | 0.95 | ALDH1A1 (0.42) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL28222242 | 0.92 | ALDH1A1 (0.40) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL9547951 | 0.89 | KCNJ1 (0.39) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL3746765 | 0.89 | DPP4 (0.37) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL7276384 | 0.89 | DPP4 (0.37) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL4797963 | 0.88 | KCNJ1 (0.38) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL2299667 | 0.87 | DPP4 (0.36) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 | |
| Trifluoroacetic Acid SCHEMBL2566861 | 0.87 | DPP4 (0.36) | ALDH1A1DPP4DPP8L3MBTL1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096321-B | Preparation method of deoxyguanosine organic synthesis intermediate | 中国医学科学院放射医学研究所 | 2021-02-12 | — | — | CN | disclosed |
| CN-109096321-A | A kind of preparation method of deoxyguanosine class organic synthesis intermediate | 中国医学科学院放射医学研究所 | 2018-12-28 | — | — | CN | disclosed |
| EP-2292610-A1 | Macrolides with VEGF transcription suppression activity | MERCIAN CORPORATION (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20060079572-A1 | Novel bioactive substance | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1380579-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1000075-A4 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1000075-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999000399-A9 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999000399-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079572-A1 | Novel bioactive substance | CASP7, MMP7, BMP4 | DPP4 729/4885MEN1 97/4885ALDH1A1 3321/4885 |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | DPP4 231/4885MEN1 829/4885ALDH1A1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.